	US 12,440,545 B2
	Methods for treating NETosis and neutrophil activation
Nelson Ruiz-Opazo, Westwood, MA (US); and Victoria L.M. Herrera, Westwood, MA (US)
Assigned to TRUSTEES OF BOSTON UNIVERSITY
Filed by TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US)
Filed on Oct. 27, 2020, as Appl. No. 17/080,944.
Application 17/080,944 is a division of application No. 16/134,070, filed on Sep. 18, 2018, granted, now 10,849,966.
Claims priority of provisional application 62/685,377, filed on Jun. 15, 2018.
Claims priority of provisional application 62/559,874, filed on Sep. 18, 2017.
Prior Publication US 2021/0121549 A1, Apr. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 9/51 (2006.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 9/08 (2006.01); C12N 9/16 (2006.01); C12N 9/50 (2006.01); C12N 9/78 (2006.01)

CPC A61K 39/001109 (2018.08) [A61K 9/51 (2013.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C12N 9/0065 (2013.01); C12N 9/16 (2013.01); C12N 9/50 (2013.01); C12N 9/78 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C12Y 111/02002 (2013.01); C12Y 301/21001 (2013.01); C12Y 304/21037 (2013.01); C12Y 304/24007 (2013.01); C12Y 305/03001 (2013.01); C12Y 305/04004 (2013.01)]

19 Claims

1. A method of preventing or decreasing neutrophil extracellular trap (NET) levels or release in a subject determined to have an increased level of NETs as indicated by the presence of Dual Endothelin/VEGF Signal Peptide Receptor (DEspR)+neutrophils or NET-forming neutrophils, as compared to a healthy subject, the method comprising administering a therapeutically effective amount of an anti-DEspR antibody reagent to the subject;

wherein the therapeutically effective amount of an anti-DEspR antibody reagent does not bind to or cause neutropenia of quiescent neutrophils or CD11b+neutrophils that do not express DEspR.